Supernus Pharmaceuticals, Inc. (SUPN) P/E Ratio History
Deep ValueTrading at -65.3x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2012–2025
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, Supernus Pharmaceuticals, Inc. (SUPN) trades at a price-to-earnings ratio of -65.3x, with a stock price of $44.38 and trailing twelve-month earnings per share of $-0.50.
The current P/E is 106% below its 5-year average of 1152.9x. Over the past five years, SUPN's P/E has ranged from a low of 8.6x to a high of 22261.5x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, SUPN trades at a 395% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, SUPN trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SUPN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SUPN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SUPN P/E vs Peers
Therapy-focused branded biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $878M | 139.6 | - | +107% | |
| $4B | 9.4 | - | +68% | |
| $2B | 6.8Lowest | 0.66Best | +817% | |
| $7B | 30.5 | - | -22% | |
| $2B | 12.3 | - | +8% | |
| $6B | 44.8 | - | +2886%Best | |
| $9B | 97.5 | - | -33% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SUPN Historical P/E Data (2012–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q2 | Jun 30 2025 | $31.52 | $1.15 | 27.4x | -95% |
| FY2025 Q1 | Mar 31 2025 | $32.75 | $1.11 | 29.5x | -95% |
| FY2024 Q4 | - | $36.16 | $1.32 | 27.4x | -95% |
| FY2024 Q3 | Sep 30 2024 | $31.18 | $1.07 | 29.1x | -95% |
| FY2024 Q2 | Jun 30 2024 | $26.75 | $0.09 | 286.7x | -47% |
| FY2023 Q4 | Dec 31 2023 | $28.94 | $0.00 | 22261.5x | +4044% |
| FY2023 Q3 | Sep 30 2023 | $27.57 | $0.41 | 67.2x | -87% |
| FY2023 Q2 | Jun 30 2023 | $30.06 | $0.73 | 41.2x | -92% |
| FY2023 Q1 | Mar 31 2023 | $36.23 | $0.89 | 40.7x | -92% |
| FY2022 Q4 | Dec 31 2022 | $35.67 | $1.03 | 34.6x | -94% |
| FY2022 Q3 | Sep 30 2022 | $33.85 | $0.64 | 52.9x | -90% |
| FY2022 Q2 | - | $28.92 | $1.01 | 28.6x | -95% |
| FY2022 Q1 | - | $32.32 | $1.30 | 24.9x | -95% |
| FY2021 Q4 | Dec 31 2021 | $29.16 | $0.98 | 29.8x | -94% |
| FY2021 Q3 | - | $26.67 | $1.51 | 17.7x | -97% |
| FY2021 Q2 | Jun 30 2021 | $30.79 | $1.85 | 16.6x | -97% |
| FY2021 Q1 | Mar 31 2021 | $26.18 | $2.07 | 12.6x | -98% |
| FY2020 Q4 | - | $25.16 | $2.36 | 10.7x | -98% |
| FY2020 Q3 | Sep 30 2020 | $20.84 | $2.41 | 8.6x | -98% |
| FY2020 Q2 | - | $23.75 | $2.21 | 10.7x | -98% |
| FY2020 Q1 | - | $17.99 | $2.17 | 8.3x | -98% |
| FY2019 Q4 | - | $23.72 | $2.11 | 11.2x | -98% |
| FY2019 Q3 | Sep 30 2019 | $27.48 | $1.97 | 13.9x | -97% |
| FY2019 Q2 | Jun 30 2019 | $33.09 | $1.95 | 17.0x | -97% |
| FY2019 Q1 | Mar 31 2019 | $35.04 | $1.91 | 18.3x | -97% |
| FY2018 Q4 | Dec 31 2018 | $33.22 | $2.06 | 16.1x | -97% |
| FY2018 Q3 | Sep 30 2018 | $50.35 | $1.84 | 27.4x | -95% |
| FY2018 Q2 | Jun 30 2018 | $59.85 | $1.61 | 37.2x | -93% |
| FY2018 Q1 | Mar 31 2018 | $45.80 | $1.36 | 33.7x | -94% |
| FY2017 Q4 | Dec 31 2017 | $39.85 | $1.06 | 37.6x | -93% |
| FY2017 Q3 | Sep 30 2017 | $40.00 | $1.06 | 37.7x | -93% |
| FY2017 Q2 | Jun 30 2017 | $43.10 | $1.95 | 22.1x | -96% |
| FY2017 Q1 | Mar 31 2017 | $31.30 | $1.81 | 17.3x | -97% |
| FY2016 Q4 | Dec 31 2016 | $25.25 | $1.70 | 14.9x | -97% |
| FY2016 Q3 | Sep 30 2016 | $24.73 | $1.58 | 15.7x | -97% |
| FY2016 Q2 | - | $20.37 | $0.48 | 42.4x | -92% |
| FY2016 Q1 | - | $15.25 | $0.34 | 44.9x | -92% |
| FY2015 Q4 | - | $13.44 | $0.28 | 48.0x | -91% |
| FY2015 Q3 | Sep 30 2015 | $14.03 | $0.24 | 58.5x | -89% |
| FY2015 Q2 | - | $16.98 | $0.81 | 21.0x | -96% |
| FY2015 Q1 | - | $12.09 | $0.85 | 14.2x | -97% |
| FY2014 Q4 | Dec 31 2014 | $8.30 | $0.45 | 18.4x | -97% |
| FY2012 Q3 | Sep 30 2012 | $11.55 | $4.38 | 2.6x | -100% |
| FY2012 Q2 | Jun 30 2012 | $9.36 | $4.23 | 2.2x | -100% |
Average P/E for displayed period: 537.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SUPN — Frequently Asked Questions
Quick answers to the most common questions about buying SUPN stock.
What is SUPN's P/E ratio?
Supernus Pharmaceuticals, Inc. (SUPN) trailing twelve-month P/E ratio is -65.3x, based on TTM diluted EPS of $-0.50. The 5-year average P/E is 1152.9x and the historical range spans 8.6x to 22261.5x.
Is SUPN stock overvalued or undervalued?
SUPN trades at -65.3x P/E, below its 5-year average of 1152.9x. At the 0th percentile of its historical range (8.6x–22261.5x), the stock is priced at a discount to its own history.
Is SUPN stock expensive?
No, SUPN is not expensive on a historical basis. The current P/E of -65.3x is below the 5-year average of 1152.9x and sits at the 0th percentile of its valuation range.
What is SUPN's historical P/E range?
Over the past 5 years, SUPN's P/E ratio has ranged from 8.6x to 22261.5x, with a median of 29.1x and an average of 1152.9x. The current P/E of -65.3x places the stock at the 0th percentile of this range. Full historical data spans 2012–2025.
How does SUPN's P/E compare to the S&P 500?
SUPN trades at -65.3x P/E versus the S&P 500 median of 24.4x. The 368% discount to the market suggests lower growth expectations or perceived higher risk.
How does SUPN's valuation compare to Healthcare peers?
Supernus Pharmaceuticals, Inc. P/E of -65.3x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is SUPN's PEG ratio?
SUPN PEG ratio is N/A, based on a P/E of -65.3x and EPS growth of -151.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is SUPN's earnings yield?
SUPN earnings yield is N/A, the inverse of its -65.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.